Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

医学 甘精胰岛素 2型糖尿病 糖尿病 内科学 磺酰脲 二甲双胍 临床终点 胰岛素 体质指数 低血糖 杜拉鲁肽 不利影响
作者
Stefano Del Prato,Steven E Kahn,Imre Pavo,Govinda J Weerakkody,Zhengyu Yang,John Doupis,Diego Aizenberg,Alan G Wynne,Jeffrey S Riesmeyer,Robert J Heine,Russell J Wiese
出处
期刊:The Lancet [Elsevier BV]
卷期号:398 (10313): 1811-1824
标识
DOI:10.1016/s0140-6736(21)02188-7
摘要

We aimed to assess efficacy and safety, with a special focus on cardiovascular safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk inadequately controlled on oral glucose-lowering medications.This open-label, parallel-group, phase 3 study was done in 187 sites in 14 countries on five continents. Eligible participants, aged 18 years or older, had type 2 diabetes treated with any combination of metformin, sulfonylurea, or sodium-glucose co-transporter-2 inhibitor, a baseline glycated haemoglobin (HbA1c) of 7·5-10·5% (58-91 mmol/mol), body-mass index of 25 kg/m2 or greater, and established cardiovascular disease or a high risk of cardiovascular events. Participants were randomly assigned (1:1:1:3) via an interactive web-response system to subcutaneous injection of either once-per-week tirzepatide (5 mg, 10 mg, or 15 mg) or glargine (100 U/mL), titrated to reach fasting blood glucose of less than 100 mg/dL. The primary endpoint was non-inferiority (0·3% non-inferiority boundary) of tirzepatide 10 mg or 15 mg, or both, versus glargine in HbA1c change from baseline to 52 weeks. All participants were treated for at least 52 weeks, with treatment continued for a maximum of 104 weeks or until study completion to collect and adjudicate major adverse cardiovascular events (MACE). Safety measures were assessed over the full study period. This study was registered with ClinicalTrials.gov, NCT03730662.Patients were recruited between Nov 20, 2018, and Dec 30, 2019. 3045 participants were screened, with 2002 participants randomly assigned to tirzepatide or glargine. 1995 received at least one dose of tirzepatide 5 mg (n=329, 17%), 10 mg (n=328, 16%), or 15 mg (n=338, 17%), or glargine (n=1000, 50%), and were included in the modified intention-to-treat population. At 52 weeks, mean HbA1c changes with tirzepatide were -2·43% (SD 0·05) with 10 mg and -2·58% (0·05) with 15 mg, versus -1·44% (0·03) with glargine. The estimated treatment difference versus glargine was -0·99% (multiplicity adjusted 97·5% CI -1·13 to -0·86) for tirzepatide 10 mg and -1·14% (-1·28 to -1·00) for 15 mg, and the non-inferiority margin of 0·3% was met for both doses. Nausea (12-23%), diarrhoea (13-22%), decreased appetite (9-11%), and vomiting (5-9%) were more frequent with tirzepatide than glargine (nausea 2%, diarrhoea 4%, decreased appetite <1%, and vomiting 2%, respectively); most cases were mild to moderate and occurred during the dose-escalation phase. The percentage of participants with hypoglycaemia (glucose <54 mg/dL or severe) was lower with tirzepatide (6-9%) versus glargine (19%), particularly in participants not on sulfonylureas (tirzepatide 1-3% vs glargine 16%). Adjudicated MACE-4 events (cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina) occurred in 109 participants and were not increased on tirzepatide compared with glargine (hazard ratio 0·74, 95% CI 0·51-1·08). 60 deaths (n=25 [3%] tirzepatide; n=35 [4%] glargine) occurred during the study.In people with type 2 diabetes and elevated cardiovascular risk, tirzepatide, compared with glargine, demonstrated greater and clinically meaningful HbA1c reduction with a lower incidence of hypoglycaemia at week 52. Tirzepatide treatment was not associated with excess cardiovascular risk.Eli Lilly and Company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
丫头完成签到,获得积分10
1秒前
Even完成签到,获得积分10
1秒前
1秒前
1秒前
香蕉觅云的应助被孟翔采纳,获得10
2秒前
2秒前
黄毛虎发布了新的文献求助10
3秒前
我是老大的应助被牛哞采纳,获得10
4秒前
YXH发布了新的文献求助10
4秒前
yang发布了新的文献求助10
4秒前
yyyy发布了新的文献求助10
4秒前
Voyager发布了新的文献求助10
5秒前
zf2023完成签到,获得积分10
5秒前
豆豆豆发布了新的文献求助10
5秒前
吴允儿发布了新的文献求助10
5秒前
6秒前
6秒前
6秒前
小兔兔猎魊完成签到,获得积分10
6秒前
多多发布了新的文献求助10
6秒前
wanci的应助被一一采纳,获得10
6秒前
书书发布了新的文献求助10
6秒前
丘比特的应助被Zzj采纳,获得10
6秒前
为何如此完成签到,获得积分20
6秒前
阳光雨堂发布了新的文献求助10
7秒前
mmknnk完成签到,获得积分10
7秒前
ian发布了新的文献求助10
7秒前
8秒前
认真白猫完成签到,获得积分20
8秒前
8秒前
cwn完成签到,获得积分10
9秒前
oxfocean完成签到,获得积分10
9秒前
9秒前
陈叉叉完成签到 ,获得积分10
9秒前
cdercder的应助被almost采纳,获得20
10秒前
guagua完成签到 ,获得积分10
10秒前
吱吱发布了新的文献求助10
10秒前
From-ZTT完成签到,获得积分10
10秒前
田様的应助被阿斯顿撒大学采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187533
求助须知:如何正确求助?哪些是违规求助? 9575604
关于积分的说明 21842148
捐赠科研通 7785275
什么是DOI,文献DOI怎么找? 3434996
关于科研通互助平台的介绍 2559428
邀请新用户注册赠送积分活动 2481898